GlassScriptPhysician profile
Sara Browning
NPI 1154961555
$696.03
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $696.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $144.91 | 2021 | |
| Puma Biotechnology, INC. | $138.87 | 2021 | |
| Myriad Genetic Laboratories, INC. | $124.77 | 2021 | |
| Glaxosmithkline, LLC. | $122.93 | 2021 | |
| Amgen INC. | $99.65 | 2021 | |
| Blueprint Medicines Corporation | $24.88 | 2021 | |
| Janssen Biotech, INC. | $21.25 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.77 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Browning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.